Cargando…
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
BACKGROUND: The reimbursement of orphan drugs (OD) is an increasingly important for country policymakers, and still insufficiently understood, especially in Central and Eastern Europe. The aim of this research was to provide a comprehensive description of country-specific health technology assessmen...
Autores principales: | Malinowski, Krzysztof Piotr, Kawalec, Paweł, Trąbka, Wojciech, Sowada, Christoph, Petrova, Guenka, Manova, Manoela, Savova, Alexandra, Draganić, Pero, Slabý, Juraj, Männik, Agnes, Márky, Kristóf, Rugaja, Zinta, Gulbinovic, Jolanta, Tesar, Tomas, Paveliu, Marian Sorin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545889/ https://www.ncbi.nlm.nih.gov/pubmed/33032634 http://dx.doi.org/10.1186/s13023-020-01556-9 |
Ejemplares similares
-
Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019) -
Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
por: Kawalec, Paweł, et al.
Publicado: (2017) -
Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017) -
Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018) -
Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)